Free and Bioavailable 25-Hydroxyvitamin D Concentrations are Associated With Disease Activity in Pediatric Patients With Newly Diagnosed Treatment Naïve Ulcerative Colitis
Author(s) -
Cary G. Sauer,
Matthew Shane Loop,
Suresh Venkateswaran,
Vin Tangpricha,
Thomas R. Ziegler,
Ashish Dhawan,
Courtney McCall,
Erin Bonkowski,
David Mack,
Brendan Boyle,
Anne M. Griffiths,
Neal S. LeLeiko,
David J. Keljo,
James Markowitz,
Susan S. Baker,
Joel R. Rosh,
Robert N. Baldassano,
Sonia M. Davis,
Shiven B. Patel,
Jessie Wang,
Alison Marquis,
Krista Spada,
Subra Kugathasan,
Thomas D. Walters,
Jeffrey S. Hyams,
Lee A. Denson
Publication year - 2018
Publication title -
inflammatory bowel diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.932
H-Index - 146
eISSN - 1536-4844
pISSN - 1078-0998
DOI - 10.1093/ibd/izx052
Subject(s) - medicine , ulcerative colitis , vitamin d and neurology , calprotectin , gastroenterology , inflammatory bowel disease , bioavailability , vitamin d deficiency , disease , pharmacology
Vitamin D regulates intestinal epithelial and immune functions, and vitamin D receptor deficiency increases the severity of murine colitis. Bioavailable 25-hydroxyvitamin D (25(OH)D) is available to target tissues and may be a driver of immune function. The aim is to evaluate the relationship of bioavailable 25(OH)D to the clinical expression of treatment naive pediatric ulcerative colitis (UC).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom